Pfizer and partner BioNTech on Friday submitted an application to the Food and Drug Administration (FDA) for emergency use authorization of their experimental CCP virus vaccine, making them the first to seek such approval.
“It is with great pride and joy and even a little relief that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA’s hands,” Pfizer CEO Albert Bourla said in a video shared on Friday. “This is a historic day, a historic day for science and for all of us. It took just 248 days to get from the day we announced our plans to collaborate with BioNTech to our FDA submission day,” he added.
